24870 Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices

Nucleotide-Deduced Amino Acid

Sequence, Isolation, and Purification of

Heat Shock Chlamydial Proteins

Morrison, R.B., Caldwell, H.D. (NIAID)

Filed 25 Feb 92

Serial No. 07/841,323 (DIV of 07/

679,302, DIV of USPN 5,071,962)

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

The chlamydial heat shock protein

(HSP60) is an immunodominant genus

common antigen which has been

implicated in immunopathologic

delayed type hypersensitivity reactions

during chlamydial infections. The HypB

gene which encodes the chlamydial

HSP60 has been cloned and

characterized. High levels of HSP60

expression have been obtained in

prokaryotic vectors and methods have

been developed for the purification of

the chlamydial HSP60 protein.

Availability of large quantities of

purified recombinant chlamydial HSP60

offers novel approaches to preventing,

treating, and diagnosing chlamydial

infections of humans. [portfolio:

Infectious Diseases—Diagnostics,

bacterial]

Methods and Compositions for

Diagnosing Cat Scratch Disease and

Bacillary Angiomatosis

Regnery, R.L., Anderson, B.E. (CDC)

Serial No. 07/822,539

Patent Issued 21 Mar 95

U.S. Patent No. 5,399,485

Licensing Contact: Carol Lavrich (301/

496–7735 ext 287)

A previously unidentified pathogenic

species of the rickettsia-like Bartonella,

named B. henselae, sp. nov., has been

identified and characterized. (Note: The

genus designation Bartonella is now

applied to and replaces the

Rochalimaea genus designation.) This

new organism causes two clinically

related diseases: Bacillary angiomatosis

and cat scratch disease. Currently,

diagnosis of Bartonella diseases is

limited to detection of the etiologic

agent associated with ‘‘trench fever’’,

referred to as B. quintata. Novel

diagnostic tests using

immunofluorescence assays or ELISAs

can detect the newly discovered

pathogen in sera from infected

individuals and distinguish it from B.

quintata, thus offering improved

differential diagnosis for disease

syndromes such as ‘‘trench fever’’,

bacillary angiomatosis, cat scratch

disease, and bacillary peliosis hepatitis.

[portfolio: Infectious Diseases—

Diagnostics, bacterial]

Effect of Cadmium on Human Ovarian

Cancer Cells With Cisplatin Resistance

Bo Lee, K., Parker, R.J., Reed, E. (NCI)

Filed 3 Mar 95

Serial No. 08/398,460

Licensing Contact: Raphe Kantor (301/

496–7735 ext 247)

The present invention describes

Cadmium (Cd) as a potential

anticarcinogenic compound useful in

treating ovarian cancer. The inventors

observed strong tumor suppressive

effects when applied to human ovarian

cancer cell lines in vitro. The effects of

Cd on cellular sensitivity, cellular drug

accumulation and efflux, and Cd-DNA

adduct formation and repair were

examined. Cadmium is shown to have a

subcellular profile that is similar,

though not identical, to cisplatin,

suggesting the possibility of future use

of CD as an anti-cancer agent. [portfolio:

Cancer—Therapeutics, conventional

chemotherapy, antimetabolites]

Trapping of Aflatoxins and

Phytoestrogens

Umrigar, P.P., Kuan, S.S. (FDA)

Filed 6 Jan 93

Serial No. 08/001,573

Licensing Contact: John Fahner-Vihtelic

(301/496–7735 ext 285)

A unique process has been invented

for removing aflatoxins and

phytoestrogens from food samples that

is a significant improvement over

currently available methods. Aflatoxins

are carcinogenic substances that are

found in foods such as grains and

peanuts and, thus, are a danger to public

health. Phytoestrogens—structurally

related to aflatoxins—are found in soy

products and also are of concern to

public health. Therefore, it is important

to be able to measure concentrations of

these compounds in foodstuffs. The

current method for determining

aflatoxin or phytoestrogen

concentrations in foods requires passing

a food sample through an affinity

column containing immobilized

antibodies specific for aflatoxins or a

solid phase extraction (SPE) column for

phytoestrogens. The bound aflatoxins or

phytoestrogens are eluted from the

affinity column and then measured

using high performance liquid

chromatography; however, such affinity

columns and SPE columns are

extremely expensive, have limited shelf

life, and cannot be reused. These

limitations have been overcome by

developing columns packed with new

derivatives of a copolymer of

cyclodextrin and epichlorohydrin.

These new copolymers, which have

proven particularly useful in trapping

aflatoxins and phyto-estrogens, are

extremely stable and are not damaged

when aflatoxins or phytoestrogens are

removed by a suitable solvent. Thus,

these materials are re-usable. [portfolio:

Devices/Instrumentation—

Miscellaneous]

Dated: May 1, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–11422 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

National Institute on Alcohol Abuse

and Alcoholism; Meetings

Pursuant to Public Law 92–463,

notice is hereby given of meetings of the

National Institute on Alcohol Abuse and

Alcoholism.

The National Advisory Council on

Alcohol Abuse and Alcoholism meeting

on June 1 will be open to the public, as

noted below, to discuss Institute

programs and other issues relating to

committee activities as indicated in the

notice. Attendance by the public will be

limited to space available. Individuals

who plan to attend and need special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contract Ida

Nestorio at 301–443–4375.

The following meetings will be closed

to the public as indicated below in

accordance with the provisions set forth

in sections 552b(c)(4) and 552b(c)(6) of

Title 5, U.S.C. and section 10(d) of

Public Law 92–463, for the review,

discussion and evaluation of individual

research grant applications. These

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Summaries of the meetings and the

rosters of committee members may be

obtained from: Ms. Ida Nestorio, Office

of Scientific Affairs, National Institute

on Alcohol Abuse and Alcoholism,

Willco Building, Suite 409, 6000

Executive Blvd., Rockville, MD 20892–

7003, Telephone: 301–443–4375. Other

information pertaining to the meetings

can be obtained from the contact person

indicated.

Name of Committee: National Advisory

Council on Alcohol Abuse and Alcoholism.

Executive Secretary: James F. Vaughan,

6000 Executive Blvd., Suite 409, Bethesda,

MD 20892–7003, 301–443–4375.

Dates of Meeting: June 1, 1995.

Place of Meeting: Delegate Room D,

Building 45 (Natcher), NIH Campus, 9000

Rockville Pike, Bethesda, MD 20892.

Open: June 1, 10:30 a.m. to adjournment.
Federal Register / Vol. 60, No. 90 / Wednesday, May 10, 1995 / Notices 24871

Agenda: Dicussion of Institute extramural

research programs, health services research,

and other program and peer review issues

relevant to Council activities.

Closed: June 1, 8 a.m. to 10:30 a.m.

Agenda: To review and evaluate grant

applications.

The following review committee meetings

will be totally closed.

Name of Committee: Neuroscience and

Behavior Subcommittee of the Alcohol

Biomedical Research Review Committee.

Dates of Meeting: June 5–7, 1995.

Time: 9 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda,

One Bethesda Metro Center, Bethesda, MD

20814.

Contact Person: Antonio Noronha, Ph.D.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–9419.

Agenda: To review and evaluate grant

applications.

Name of Committee: Clinical and

Treatment Subcommittee of the Alcohol

Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda,

One Bethesda Metro Center, Bethesda, MD

20814.

Contact Person: Elsie D. Taylor, Scientific

Review Administrator, 6000 Executive Blvd,

Suite 409, Bethesda, MD 20892–7003, 301–

443–9787.

Agenda: To review and evaluate grant

applications.

Name of Committee: Epidemiology and

Prevention Subcommittee of the Alcohol

Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn, 480 King

Street, Alexandra, VA.

Contact Person: Thomas D. Sevy, M.S.W.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–6106.

Agenda: To review and evaluate grant

applications.

Name of Committee: Biochemistry,

Physiology, and Medicine Subcommittee of

the Alcohol Biomedical Research Review

Committee.

Dates of Meeting: June 15–17, 1995.

Place of Meeting: Double Tree Hotel,

Denver, CO.

Time: 9 a.m. to adjournment.

Contact Person: Ronald Suddendorf, Ph.D.,

Scientific Review Administrator, 6000

Executive Blvd, Suite 409, Bethesda, MD

20892–7003, 301–443–2932.

Agenda: To review and evaluate grant

applications.

(Catalog of Federal Domestic Assistance

Program No. 93.271, Alcohol Research Career

Development Awards for Scientists and

Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

93.281, Scientist Development Award,

Research Scientist Development Award,

Scientist Development Award for Clinicians,

and Research Scientist Award; 93.891,

Alcohol Research Center Grants; National

Institutes of Health).

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–11421 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and

Musculoskeletal and Skin Disease;

Notice of Meeting of the National

Arthritis and Musculoskeletal and Skin

Diseases Advisory Council

Pursuant to Public Law 92–463,

notice is hereby given of a meeting of

the National Arthritis and

Musculoskeletal and Skin Diseases

Advisory Council to provide advice to

the National Institute of Arthritis and

Musculoskeletal and Skin Diseases on

June 1 and 2, 1995, Conference Room 6,

Building 31, National Institutes of

Health, Bethesda, Maryland.

The meeting will be open to the

public June 1 from 8:30 a.m. to 9 a.m.

to discuss administrative details relating

to Council business and special reports.

Attendance by the public will be limited

to space available.

The meeting of the Advisory Council

will be closed to the public on June 1

from 9 a.m. to approximately 5 p.m. and

if necessary the closed portion will

continue on June 2 from 8:30 a.m. to

adjournment in accordance with

provisions set forth in secs. 552b(c)(4)

and 552b(c)(6), Title 5, U.S.C. and

section 10(d) of Public Law 92–463, for

the review, discussion and evaluation of

individual grant applications. These

deliberations could reveal confidential

trade secrets or commercial property,

such as patentable materials, and

personal information concerning

individuals associated with the

applications, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Individuals who plan to attend and

need special assistance, such a sign

language interpretation or other

reasonable accommodations, should

contact Dr. Tommy Broadwater,

Executive Secretary, National Arthritis

and Musculoskeletal and Skin Diseases

Advisory Council, NIAMS, Natcher

Building, Room 5AS–13, Bethesda,

Maryland 20892, (301) 594–2463.

A summary of the meeting and roster

of the members may be obtained from

the Extramural Programs Office,

NIAMS, Natcher Bldg., Rm. 5AS–13,

National Institutes of Health, Bethesda,

Maryland 20892, (301) 594–2463.

(Catalog of Federal Domestic Assistance

Program No. 93.846, Arthritis, Bone and Skin

Diseases, National Institutes of Health)

Dated: May 3, 1995.

Susan K. Feldman,

NIH Committee Management Officer.

[FR Doc. 95–11419 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Meeting

Notice is hereby given of the meeting

of the National Heart Attack Alert

Program Coordinating Committee,

sponsored by the National Heart, Lung,

and Blood Institute on June 13, 1995,

from 8:30 a.m. to 3:15 p.m., at the

Bethesda Holiday Inn Hotel, 8120

Wisconsin Avenue, Bethesda, Maryland

20814, (301) 652–2000.

The entire meeting is open to the

public. The Coordinating Committee is

meeting to discuss the progress of the

National Heart Attack Alert Program

with its participating organizations.

Attendance by the public will be limited

to space available.

For the detailed program information,

agenda, list of participants, and meeting

summary, contact: Ms. Mary McDonald

Hand, Coordinator, National Heart

Attack Alert Program, Office of

Prevention, Education and Control,

National Heart, Lung, and Blood

Institute, National Institutes of Health,

31 Center Drive MSC 2480, Bethesda,

Maryland 20892–2480, (301) 496–1051.

Dated: May 3, 1995.

Claude Lenfant,

Director, NHLBI.

[FR Doc. 95–11425 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

National Institute of Mental Health;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Institute of

Mental Health Special Emphasis Panel:

Agenda/Purpose

To review and evaluate grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 5, 1995.

Time: 2 p.m.

Place: Parklawn Building, Room 9C–26,

5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis D. Artis, Grant

Technical Assistant, Parklawn Building,

Room 9C–26, 5600 Fishers Lane, Rockville,

MD 20857, Telephone: 301, 443–6470.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 6, 1995.

Time: 12:30 p.m.

Place: Parklawn Building, Room 9C–26,

5600 Fishers Lane, Rockville, MD 20857.